Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
14
14 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- ezetimibe FDCPhase 32 trials
NewAmsterdam Pharma · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
- EA-230hourPhase 31 trial
EBI Anti Sepsis BV · Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
- XTR00499mTechnicium Sestamibi, Procedure: Coronary angiographyPhase 31 trial
Sinotau Pharmaceutical Group · Coronary Artery Disease(CAD)
- SRSD107Phase 22 trials
Sirius Therapeutics Co., Ltd. · Venous Thromboembolism, Coronary Artery Disease (CAD), Peripheral Arterial Disease
- YN001Phase 22 trials
Beijing Inno Medicine Co., Ltd. · Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease
- A195Phase 21 trial
XyloCor Therapeutics, Inc. · Coronary Artery Disease (CAD)
- HeXell-2020Phase 21 trial
Hexun Biosciences Co., LTD. · Coronary Artery Disease
- RBD1119Phase 21 trial
Ribocure Pharmaceuticals AB · Stable Coronary Artery Disease
- RBD4059Phase 21 trial
Ribocure Pharmaceuticals AB · Stable Coronary Artery Disease CAD
- XC001Phase 21 trial
XyloCor Therapeutics, Inc. · Coronary Artery Disease (CAD)
- YMI024Phase 21 trial
Novartis · Coronary Artery Disease
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.